Intel Debuts Core Series 2 Chips, Healthcare Edge AI Suite

Intel unveiled a new generation of edge computing processors and a healthcare-focused AI development suite at Embedded World 2026, expanding its portfolio for real-time industrial systems and AI-powered patient monitoring. 

The company introduced its Intel Core Series 2 processors with P-cores, an industrial-ready platform designed for mission-critical edge workloads. 

Alongside the processor launch, Intel also previewed its Edge AI Suite for Health & Life Sciences, which includes validated AI pipelines and benchmarking tools to help technology vendors build and test AI-enabled patient-monitoring applications that run locally on Intel hardware. 

Intel Core Series 2 designed for edge applications and real-time performance

The company introduced the Intel Core Series 2 processors with performance cores (P-cores), designed for mission-critical edge applications requiring deterministic real-time performance. 

“Intel continues to lead in edge computing, which remains one of our fastest-growing business segments,” said Dan Rodriguez, Intel corporate vice president and general manager of the Edge Computing Group. 

“With the introduction of Core Series 2, our CES launch of Core Ultra Series 3, and our expanding Edge AI Suites, we continue to deliver comprehensive platforms that meet diverse edge customer needs with breakthrough performance, reliability, and integrated AI acceleration,” Rodriguez continued.

Processors target industrial edge workloads

According to Intel, the new Core Series 2 processors are designed to address growing industrial demands for platforms capable of managing multiple critical workloads simultaneously. 

Manufacturing environments increasingly require processors that support safety-critical control systems, real-time analytics, and operational workloads while maintaining predictable timing and deterministic performance.

Traditional processors often force organizations to balance computational power against real-time reliability, leading to complex multi-processor architectures that increase costs and system complexity. 

Intel said its Core Series 2 platform is designed to address those challenges while delivering improved performance metrics.

Intel touts performance improvements compared to AMD Ryzen

Compared with AMD’s Ryzen 7 9700X processor, Intel said the new platform provides up to 4.4 times lower maximum PCIe latency, 2.5 times more deterministic response time, 3.8 times better deterministic performance, and up to 1.5 times higher multi-thread performance in testing scenarios.

These capabilities are intended to support use cases such as industrial automation, robotics, and other edge environments where deterministic processing and real-time performance are essential.

AI suite expands edge healthcare capabilities

Alongside the processor launch, Intel previewed its Edge AI Suite for Health & Life Sciences, which focuses on AI-powered patient monitoring systems.

Healthcare providers are facing rising patient volumes and ongoing workforce shortages, driving demand for more automated monitoring technologies. 

Intel said patient monitoring systems are evolving from standalone devices to connected ecosystems that require local AI processing for faster insights and reliable operation.

The Edge AI suite includes validated reference pipelines and benchmarking tools designed to help technology vendors evaluate AI workloads in real-world scenarios. 

The suite supports concurrent, multimodal workloads running locally on Intel processors, including AI-based electrocardiogram arrhythmia detection, remote photoplethysmography, and anonymous 3D visual tracking.

OEMs, ODMs, and ISVs focused on healthcare applications are set to benefit

Intel said the tools are intended for original equipment manufacturers (OEMs), original design manufacturers (ODMs), and independent software vendors (ISVs) building healthcare applications. 

Rather than relying on synthetic benchmarks, the reference workflows are designed to simulate representative patient monitoring environments.

Availability and broader edge portfolio

The Core Series 2 processors join Intel’s broader edge computing portfolio, including the previously launched Core Ultra Series 3 processors, to support use cases ranging from real-time industrial control to AI acceleration across manufacturing, healthcare, and other edge deployments.

Systems powered by both the Core Ultra Series 3 and Core Series 2 processors are available now. Intel said a preview version of the Health & Life Sciences Edge AI Suite is available on GitHub, with general availability expected in the second quarter of 2026.